Frost & Sullivan Independent Equity Research
BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations
![bioline bioline](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/bioline-nx7oepmjwr0nqu046yc3t5fs9jyo1sg30b9j97eohk.png)
Company: BioLineRx
Sector: Pharmaceuticals
Report type: Q1-2018 and 12 months since Initiation Updates
For all past reports click here
Published on: 27 June, 2018